HOME ·

Clinical Progress

SBP GROUP (01177.HK): Kylo-11 Phase I data published in The Lancet; single dose reduces Lp(a) by up to 97% at week 48
Tags：
SBP GROUP01177.HKClinical Progress
2026-08-31
TYK MEDICINES-B (02410.HK): Dovatinib mesylate tablets (TY-9591) granted conditional approval as first-line treatment for EGFR-mutant NSCLC with CNS metastases
Tags：
TYK MEDICINES-B02410.HKClinical Progress
2026-08-27
FOSUN PHARMA (02196.HK): Licensed drug weliteitumab injection (GR1803) granted conditional approval for relapsed or refractory multiple myeloma
Tags：
FOSUN PHARMA02196.HKClinical Progress
2026-08-27
SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
Tags：
SSY Group02005.HKClinical Progress
2026-08-27
LIVZON PHARMA (01513.HK): Lecankitug injection approved for marketing; first domestic IL-17A/F dual-target biologic in China
Tags：
LIVZON PHARMA01513.HKClinical Progress
2026-08-27
LUYE PHARMA (02186.HK): therapeutic mRNA vaccine LY01620 to initiate Phase II clinical trial in China, HPV viral clearance rate nearly 90%
Tags：
LUYE PHARMA02186.HKClinical Progress
2026-08-21
LONGBIO-B (01779.HK): BLA of LP-003 for seasonal allergic rhinitis accepted by NMPA
Tags：
LongBio-B01779.HKClinical Progress
2026-08-21
LEADS BIOLABS-B (09887.HK): Phase II study abstract of Vimx (opasumivimab) as first-line NSCLC therapy published on WCLC website
Tags：
LEADS BIOLABS-B09887.HKClinical Progress
2026-08-20
LEADS BIOLABS-B (09887.HK): Oblenio exercises option to retain license for LBL-051, Company to receive USD 10 million
Tags：
LEADS BIOLABS-B09887.HKClinical Progress
2026-08-20